AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
1-Year Est. Return
18.84%
1 Year Est. Return
+18.84%
AUM
$100M
AUM Growth
-$34.3M
(-25%)
Holding
294
Top Buys
| 1 | +$4.74M | |
| 2 | +$3.6M | |
| 3 | +$2.63M | |
| 4 |
AbbVie
ABBV
|
+$2.31M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$2.17M |
Top Sells
| 1 | +$4.32M | |
| 2 | +$3.88M | |
| 3 | +$3.12M | |
| 4 |
EFC
Ellington Financial
EFC
|
+$2.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$2.57M |
Sector Composition
| 1 | Healthcare | 54.58% |
| 2 | Real Estate | 7.4% |
| 3 | Industrials | 5.96% |
| 4 | Financials | 5.87% |
| 5 | Technology | 4.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Star Holdings Shares of Beneficial Interest
STHO
$98.9M
| – | – |
-7,744
|
|
||
277
Takeda Pharmaceutical
TAK
$44.3B
| – | – |
-80,000
|
|
||
278
Tourmaline Bio
TRML
$1.23B
| – | – |
-5,500
|
|
||
279
United Therapeutics
UTHR
$19.6B
| – | – |
-6,250
|
|
||
|
VALN
280
Valneva
VALN
$862M
| – | – |
-118,000
|
|
||
281
Vera Therapeutics
VERA
$1.99B
| – | – |
-7,500
|
|
||
282
Viking Therapeutics
VKTX
$3.77B
| – | – |
-3,500
|
|
||
283
Vanguard Global ex-US Real Estate ETF
VNQI
$3.53B
| – | – |
-4,021
|
|
||
284
Viridian Therapeutics
VRDN
$1.98B
| – | – |
-15,000
|
|
||
285
VYNE Therapeutics
VYNE
$9.63M
| – | – |
-268,485
|
|
||
286
SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
$345M
| – | – |
-2,514
|
|
||
287
ArriVent BioPharma
AVBP
$792M
| – | – |
-15,000
|
|
||
|
ONIT
288
Onity Group
ONIT
$289M
| – | – |
-25,567
|
|
||
|
ONC
289
BeOne Medicines Ltd
ONC
$34.8B
| – | – |
-5,500
|
|
||
|
ITCI
290
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-20,000
|
|
||
|
RVNC
291
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-245,000
|
|
||
292
Cytokinetics
CYTK
$6.99B
| – | – |
-12,500
|
|